Literature DB >> 29431018

Multimodality treatment of operable gastric and oesophageal adenocarcinoma: evaluating neoadjuvant, adjuvant and perioperative approaches.

Michael Davidson1, Ian Chau1.   

Abstract

INTRODUCTION: Treatment patterns for locally advanced operable gastric and oesophageal adenocarcinoma vary, with the optimal approach an area of debate within oncology. Strategies for treatment include a variety of neo-adjuvant, adjuvant and peri-operative regimens involving differing chemotherapy and radiotherapy combinations. Areas covered: This review will critically appraise the evidence base underpinning the main treatment approaches in operable oesophagogastric adenocarcinoma, highlighting variations in treatment by factors such as geographical area and primary tumor site. Expert commentary: The expert commentary will focus on the optimal evidence-based approaches for clinicians at the present time and explore how increased understanding of the molecular and genetic determinants of the disease may lead to refinements in treatment through the development of both biomarker-driven approaches and the application of novel targeted and immune-modulating agents to early treatment.

Entities:  

Keywords:  Gastric; adjuvant; cancer; neoadjuvant; oesophageal; operable

Mesh:

Substances:

Year:  2018        PMID: 29431018     DOI: 10.1080/14737140.2018.1438271

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  3 in total

1.  Anlotinib combined with SOX regimen (S1 (tegafur, gimeracil and oteracil porassium capsules) + oxaliplatin) in treating stage IV gastric cancer: study protocol for a single-armed and single-centred clinical trial.

Authors:  Juan Wang; Dong Xue Wu; Lu Meng; Gang Ji
Journal:  BMJ Open       Date:  2020-06-03       Impact factor: 2.692

2.  Neoadjuvant radiotherapy for locoregional Siewert type II gastroesophageal junction adenocarcinoma: A propensity scores matching analysis.

Authors:  Yuan Zhou; MengXiang Tian; Cenap Güngör; Dan Wang
Journal:  PLoS One       Date:  2021-05-12       Impact factor: 3.240

Review 3.  Relevant issues in tumor regression grading of histopathological response to neoadjuvant treatment in adenocarcinomas of the esophagus and gastroesophageal junction.

Authors:  F Klevebro; A Tsekrekos; D Low; L Lundell; M Vieth; S Detlefsen
Journal:  Dis Esophagus       Date:  2020-06-15       Impact factor: 3.429

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.